v3.26.1
General (Details)
$ / shares in Units, $ in Thousands, € in Millions
1 Months Ended 2 Months Ended 12 Months Ended
Sep. 11, 2025
USD ($)
Sep. 10, 2025
USD ($)
shares
Mar. 27, 2025
USD ($)
Mar. 24, 2025
shares
Mar. 03, 2025
USD ($)
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Aug. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2025
EUR (€)
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
General [Line Items]                      
Entity Incorporation, Date of Incorporation               Jul. 21, 2003 Jul. 21, 2003    
Revenues               $ 1,311   $ 658
Total research and development expenses               2,369   5,532 5,210
Consideration installments payment amount $ 75                    
Cash and cash equivalents               1,661   1,964 4,870
Operating loss               (7,542)   $ (8,638) $ (9,706)
Cash flows from operating activities               (6,081)      
Option Agreement [Member]                      
General [Line Items]                      
Total consideration amount               200      
Signing paid amount $ 150                    
Remaining paid amount               150      
Non-dilutive grant funding amount (in Euro) | €                 € 11    
Development funding amount               3,000      
Additional cancellation fee payable               50      
Total research and development expenses               250      
Liability               $ 50      
Standby Equity Purchase Agreement [Member]                      
General [Line Items]                      
Shares issued (in Shares) | shares         28,784            
Issuance-related finance costs         $ 150            
Volume weighted average price percentage         97.00%     97.00% 97.00%    
Gross proceeds amount             $ 4,203        
Volume-weighted average price (in Dollars per share) | $ / shares             $ 2.57        
Discount market price percentage             3.00%        
Transaction shartes issued (in Shares) | shares             1,638,062        
Commitment amount   $ 15,000                  
Issuance of ordinary shares (in Shares) | shares   4,000                  
Polish [Member]                      
General [Line Items]                      
Total consideration amount               $ 1      
Acquire percentage               100.00%      
PinCell [Member]                      
General [Line Items]                      
Acquire percentage               100.00%      
PinCell [Member] | Option Agreement [Member]                      
General [Line Items]                      
Signing paid amount               $ 50      
Scinai Bioservices Inc [Member]                      
General [Line Items]                      
Revenues               $ 502      
American Depositary Shares [Member] | Standby Equity Purchase Agreement [Member]                      
General [Line Items]                      
Aggregate purchase price amount         $ 10,000            
Sale shares issued (in Shares) | shares           511,690   3,022,796 3,022,796    
Gross proceeds amount           $ 1,492 $ 4,203        
Volume-weighted average price (in Dollars per share) | $ / shares           $ 2.9 $ 2.57        
Discount market price percentage           3.00% 3.00%        
Transaction shartes issued (in Shares) | shares             1,638,062        
Commitment amount   $ 108,000                  
Issuance of ordinary shares (in Shares) | shares   35,461                  
Commitment fee percentage   50.00%                  
Cash payable percentage   50.00%                  
Commitment Shares [Member] | American Depositary Shares [Member] | Standby Equity Purchase Agreement [Member]                      
General [Line Items]                      
Sale shares issued (in Shares) | shares       31,746              
Gross proceeds amount     $ 104